| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac5d5f82c11f8d94ae98ea9d0b033404 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5192 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate |
2018-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a152a0762ee8936d127a80fcdf74244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffb6157ce295f5b75d0b0bcab4fcc80b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461047c7608ce6c830b7d514d683032a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad950c76f2f803eebf1487a0015f6ef5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c26c3fad118deb3cffed49d0aef1a210 |
| publicationDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018145185-A1 |
| titleOfInvention |
Use of diethylcarbamazine incorporated to pharmaceutical compositions for the treatment and/or prevention of inflammatory diseases in human or animal |
| abstract |
The present invention described the use of an effective amount of diethylcarbamazine (DEC), or its pharmaceutically acceptable salts, incorporated to pharmaceutical and/or veterinary compositions, in the production of a medicament for the treatment and/or prevention of inflammatory pathologies, which may be associated with fibrotic processes, in human beings and animals. The incorporation of DEC or its pharmaceutically acceptable salts in to a pharmaceutical and/or veterinary composition promotes an increase in the anti-inflammatory and anti-fibrotic activities when compared to the administration of DEC alone. |
| priorityDate |
2017-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |